Theriva Biologics Inc (TOVX) Company Sales

Investing in Theriva Biologics, Inc. (TOVX) entails volatility due to a lack of sales and uncertainty regarding test results. However, M&A potential and the orphan drug status of VCN-01 create strong growth drivers. The business is currently in a phase of awaiting regulatory verdicts without stable revenue sources. 0.00 is the current value of the metric, as clearly demonstrated by the company's sales revenue chart.
Analytical breakdowns for Theriva Biologics Inc (TOVX)

This metric captures the daily cash inflow from product sales, allowing investors to assess the business's actual liquidity regardless of market noise. Analyzing the sales statistics of Theriva Biologics, Inc. (TOVX) helps distinguish stable operating income from random spikes, which is critically important for Theriva Biologics, Inc. (TOVX) given the inelastic demand for its unique tumor-destruction technology.